Article Figures & Data
Figures
- Figure 1.
Radiographic response to erlotinib in patients with adenosquamous and solid pseudosquamous adenocarcinomas harboring EGFR mutations. †, denotes solid (pseudosquamous) adenocarcinomas; other cases are carcinomas with a squamous component (confirmed or presumed adenosquamous carcinomas).
- Figure 2.
Kaplan–Meier survival curve for progression-free survival (PFS) in patients with EGFR-mutant adenosquamous and solid pseudosquamous adenocarcinomas treated with erlotinib. NR, not reached; TTP, time to progression.
- Figure 3.
Kaplan–Meier survival curve for overall survival (OS) in patients with EGFR-mutant adenosquamous and solid pseudosquamous adenocarcinomas treated with erlotinib. NR, not reached.
Tables
- Table 1.
Clinicopathologic findings for patients with EGFR-mutant adenosquamous carcinomas
Patienta Age Gender Race Smoking status Stageb Biopsy #1c Biopsy #1 mutation Biopsy #2c Biopsy #2 mutation Lines of therapy EGFR TKI line Best response to EGFR TKI TTP on TKI (months) OS (months) 1 (1) 61 M White Never IV Squamous (L1)d exon 19 del Adenosquamous (LLL lung) exon 19 del 3 2nd line PR 12.1 27.5 2 (2) 71 F White Never IV Squamous (RLL lung)d exon 19 del Adenocarcinoma (RLL lung) exon 19 del 2 1st line Unavailable 19.6 32.9+ 3 (3) 58 F White Never IV Squamous (RUL lung) exon 19 del Adenosquamous (LLL lung)† exon 19 del 3 2nd line SD 23.6 32.2+ 4 (4) 45 F Hispanic Never IV Squamous (sacrum) exon 19 del Adenocarcinoma (pleural fluid) exon 19 del 2 2nd line Unavailable Unavailable 15.3 5 (5) 46 M Asian Never IV Squamous (R lung) exon 19 del Adenocarcinoma (SC LN) exon 19 del 1 1st line PR 5.0+ 6.6+ 6 (6) 73 M White Former (25 PY) IV Squamous (adrenal) exon 19 del Adenocarcinoma (SC LN) insufficient 2 3rd line Unavailable Unavailable 29.8 7 (10) 58 M Asian Never IV Squamous (bronchus) L858R Squamous (T8) insufficient 1 1st line PR 1.9 2.5 8 (new) 76 M White Never IVe Squamous (R lung)d insufficient Adenocarcinoma (L lung) exon 19 del 1 1st line PR 5.3 5.3+ 9 (new) 68 M White Never IV Squamous (L lung) L858R None N/A 4 4th line PR 2.8+ 24.0+ 10 (new) 30 F Asian Never IV Adenosquamous (R lung) L858R None N/A 2 1st line PR 8.4 10.9+ 11 (new) 50 M White Never IV Adenosquamous (L lung) exon 19 del None N/A 1 1st line PR 9.2+ 9.6+ Abbreviations: SC LN, supraclavicular lymph node; PR, partial response; SD, stable disease; PY, pack years; TTP, time to progression.
NOTE: The majority of patients were diagnosed with squamous cell carcinoma in at least 1 sample.
-
↵aIn parentheses are corresponding patient IDs in reference 8.
-
↵bStage at the time of TKI treatment.
-
↵cBiopsy numbers are not chronological: biopsy #1 represents the index case (EGFR mutant SCC).
-
↵dAcquired resistance biopsy.
-
↵ePrevious stage IIA treated with induction cisplatin + pemetrexed followed by LLL lobectomy, with subsequent development of bilateral pulmonary nodules and a recurrent parenchymal lesion at the lobectomy site.
- Table 2.
Clinicopathologic findings for patients with EGFR-mutant solid pseudosquamous adenocarcinomas
Patienta Age Gender Race Smoking status Stageb Initial diagnosis (site) Mutation Re-review Lines of therapy EGFR TKI line Best response to EGFR TKI TTP on TKI (months) OS (months) 12 (11) 89 F Asian Never IV Squamous (lung) L858R Adenocarcinoma 1 1st line SD 7.6 16.5 13 (12) 53 F White Former (31) IVc Squamous (lung) exon 19 del Adenocarcinoma 1 1st line PR 12.4 20.6+ NOTE: Both patients were initially diagnosed with squamous cell carcinomas.
Abbreviation: TTP, time to progression.
Volume 11, Issue 11
